SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing
16 references·0 citing·46 second hop
Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing (2019)Evolution of Average European Medicine Pr…The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications (2017)The Implementation of Managed…Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future (2017)Managed Entry Agreements for …How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries (2017)How Can Pricing and Reimburse…Arzneiverordnungs-Report 2017 (2017)Arzneiverordnungs-Report 2017Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis (2016)Prices, Costs, and Affordabil…ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe (2016)ESMO European Consortium Stud…Overview of external reference pricing systems in Europe (2015)Overview of external referenc…Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review (2015)Disinvestment and Value-Based…Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study (2015)Cancer drugs in 16 European c…Actual costs of cancer drugs in 15 European countries (2015)Actual costs of cancer drugs …Shortages of medicines: a complex global challenge (2012)Shortages of medicines: a com…Differences in external price referencing in Europe—A descriptive overview (2011)Differences in external price…Canʼt Get No Satisfaction? Will Pay for Performance Help? (2010)Canʼt Get No Satisfaction? Wi…Pharmaceutical pricing policies in a global market (2008)Pharmaceutical pricing polici…Pharmaceutical Price Controls and Entry Strategies (2007)Pharmaceutical Price Controls…The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)The impact of price regulatio…Economic Efficiency and the Distribution of Benefits from College Instruction (1970)Expected value of information and decision making in HTA (2006)Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement (2011)Uncertainty and the Evaluation of Public Investment Decisions (2013)Italian risk-sharing agreements on drugs: are they worthwhile? (2014)Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy (1993)The Regulation of Entry (2000)Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)International Prices And Availability Of Pharmaceuticals In 2005 (2008)Patents and the Global Diffusion of New Drugs (2015)Cross-national price differences for pharmaceuticals: how large, and why? (2000)The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries─an overview (2012)Value in Pharmaceutical Pricing (2013)Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries (2014)Delivering affordable cancer care in high-income countries (2011)Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012)Economic burden of cancer across the European Union: a population-based cost analysis (2013)Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund (2017)An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access (2021)Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2014)World Development indicators (2015)A global comparison of the cost of patented cancer drugs in relation to global differences in wealth (2017)Pricing of pharmaceuticals is becoming a major challenge for health systems (2020)International Labour Organization (2022)Fairness as a Constraint on Profit Seeking: Entitlements in the Market (2000)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe (2017)Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies (2019)Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe (2020)Access to medicines from a health system perspective (2012)Pricing in the Market for Anticancer Drugs (2015)Essential medicines for universal health coverage (2016)Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)Managed Entry Agreements: Policy Analysis From the European Perspective (2020)A global perspective on the issue of access to insulin (2021)How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question (2009)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients (2015)Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis (2020)Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure (2021)An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments (1973)Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)Market size and pharmaceutical innovation (2015)Drug shortages in European countries: a trade-off between market attractiveness and cost containment? (2014)Insights into European Drug Shortages: A Survey of Hospital Pharmacists (2015)Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications (2020)
this work references cited by second hop

References

  • 2004The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s344 cited
  • 2007Pharmaceutical Price Controls and Entry Strategies298 cited
  • 2016Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis255 cited
  • 2017How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries203 cited
  • 2015Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study175 cited
  • 2016ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe172 cited
  • 2017Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future142 cited
  • 2012Shortages of medicines: a complex global challenge136 cited
  • 2011Differences in external price referencing in Europe—A descriptive overview132 cited
  • 2010Canʼt Get No Satisfaction? Will Pay for Performance Help?124 cited
  • 2017The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications122 cited
  • 2008Pharmaceutical pricing policies in a global market107 cited
  • 2015Overview of external reference pricing systems in Europe104 cited
  • 2015

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Actual costs of cancer drugs in 15 European countries
98 cited
  • 2017Arzneiverordnungs-Report 201796 cited
  • 2015Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review92 cited
  • Cited by

    No citing works inside the corpus for this window.